Wegovy

Wegovy® (semaglutide), an FDA-approved GLP-1 receptor agonist, treats obesity (BMI≥30) or overweight (BMI≥27) with comorbidities like hypertension. In 68-week trials, patients achieved 15% mean weight loss (35 lb from 232 lb baseline), with 86% losing ≥5% and 30% ≥20%. Regulates hypothalamic appetite signals and delays gastric emptying for sustained effects. Features a 5-step dose escalation protocol (20 weeks) to minimize GI intolerance, while improving BP, lipids, and HbA1c for long-term weight maintenance.